The European Commission’s recent authorization of AstraZeneca’s Imfinzi marks a significant shift in the therapeutic landscape for patients battling resectable gastric and gastro-esophageal junction cancers across the continent. This decision formalized the use of durvalumab as a perioperative
Managing the dual burden of skin inflammation and joint pain requires more than just temporary relief; it demands a sophisticated therapeutic approach that targets the underlying causes of psoriatic disease. The expansion of oral options for adults with active psoriatic arthritis signifies a shift
Ivan Kairatov is at the forefront of biopharmaceutical innovation, specializing in how next-generation therapies reshape the landscape of oncology. With a robust background in research and development, he has monitored the evolution of multiple myeloma treatments from traditional chemotherapies to
Modern medicine often forces patients with systemic lupus erythematosus into a difficult trade-off between managing life-threatening organ damage and enduring the harsh, systemic toxicity of long-term steroid use. While existing treatments offer some relief, they frequently fail to address the
The digital age has transformed how individuals manage their most intimate health details, yet a recent legal filing suggests that the promise of absolute privacy might be more of a marketing strategy than a technical reality. Natural Cycles, the first company to receive FDA clearance for a digital
For decades, millions of individuals living with vitiligo have navigated a healthcare system that largely dismissed their condition as a minor cosmetic inconvenience rather than a significant autoimmune challenge. This landscape shifted decisively following the approval of ruxolitinib (Opzelura) by
